Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529822 · ClinicalTrials.gov registry record · Phase 1
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
A Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06529822 is a Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 32 participants, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06529822, a Phase 1 study of Muscle-Invasive Bladder Carcinoma and Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Conditions Studied
Interventions
- BIOLOGICAL Synthetic long peptide personalized cancer vaccine
- DRUG Poly ICLC
- DEVICE Signatera assay
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2033-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06529822
The ClinicalTrials.gov registry entry for NCT06529822 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (74% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Synthetic long peptide personalized cancer vaccine is the first listed.
NCT06529822 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06529822 about?
NCT06529822 is a clinical study titled "Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease". This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and cap...
What is the current status of trial NCT06529822?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-03-20. Estimated completion is 2033-03-31.
What conditions does trial NCT06529822 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT06529822?
The interventions under investigation include: Synthetic long peptide personalized cancer vaccine (BIOLOGICAL), Poly ICLC (DRUG), Signatera assay (DEVICE).
Who is sponsoring clinical trial NCT06529822?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529822 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Prophylactic Antibiotics in Cystectomy With Diversion
RECRUITING · Early Phase 1
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
RECRUITING · NA
Explore more on PlainTrial
Muscle-Invasive Bladder Carcinoma
All registered trials for this condition
Gastroesophageal Adenocarcinoma
All registered trials for this condition
Missouri
All trials with a study site in Missouri
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.